Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · May 14, 2022

Utility of C-Peptide Levels for Predicting the Magnitude of Glycemic Benefits in Patients With Type 2 Diabetes

Diabetes Technology & Therapeutics

 

Additional Info

Diabetes Technology & Therapeutics
With or Without Residual C-Peptide, Patients with Type 2 Diabetes Realize Glycemic Benefits from Real-Time Continuous Glucose Monitoring
Diabetes Technol. Ther. 2022 Apr 01;24(4)281-284, R Bailey, P Calhoun, C Chao, TC Walker

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading